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Abstract
Background: To assess the relationship between radiation doses to the coronary arteries (CAs) and location of a
coronary stenosis that required intervention after three-dimensional conformal radiotherapy (3DCRT) for breast
cancer (BC).
Methods: The study population consisted of 182 women treated for BC in Sweden between 1992 and 2012. All
women received 3DCRT and subsequently underwent coronary angiography due to a suspected coronary event.
CA segments were delineated in the patient’s original planning-CT and radiation doses were recalculated based on
the dose distribution of the original radiotherapy (RT) plan. The location of the CA stenosis that required
intervention was identified from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Logistic
regression analysis was used to assess the relationship between CA radiation doses and risk of a later coronary
intervention at this specific location.
Results: The odds ratio (OR) varied by radiation dose to the mid left anterior descending artery (LAD) (p = 0.005).
Women receiving mean doses of 1–5 Gray (Gy) to the mid LAD had an adjusted OR of 0.90 (95% CI 0.47–1.74) for
a later coronary intervention compared to women receiving mean doses of 0–1 Gy to the mid LAD. In women
receiving mean doses of 5–20 Gy to the mid LAD, an adjusted OR of 1.24 (95% CI 0.52–2.95) was observed, which
increased to an OR of 5.23 (95% CI 2.01–13.6) for mean doses over 20 Gy, when compared to women receiving
mean doses of 0–1 Gy to the mid LAD.
Conclusions: In women receiving conventional 3DCRT for BC between 1992 and 2012, radiation doses to the LAD
remained high and were associated with an increased requirement of coronary intervention in mid LAD. The results
support that the LAD radiation dose should be considered in RT treatment planning and that the dose should be
kept as low as possible. Minimising the dose to LAD is expected to diminish the risk of later radiation-induced
stenosis.
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Background
Adjuvant radiotherapy (RT) in early breast cancer (BC)
significantly reduces local recurrences and death in BC
and is considered as a part of standard treatment [1, 2].
However, due to incidental radiation exposure to the
heart, RT has been associated with increased risk of is-
chemic heart disease (IHD) [3–6]. Dosimetry studies
have shown that the left anterior descending artery
(LAD) receives the highest radiation doses in RT for
left-sided BC [7, 8] and a higher incidence of LAD sten-
osis has been reported after RT of left-sided compared
to right-sided BC [9, 10]. Radiation volumes and doses
to the heart have changed with the development of new
techniques, although doses to the anterior part of the
heart may still be high [7, 11, 12]. RT techniques using
active breathing control (ABC) have shown to further re-
duce the radiation doses to the heart and LAD [13, 14].
There are uncertainties concerning the dose-response
relationship between absorbed dose to the whole heart
and the coronary arteries (CAs), and subsequent coron-
ary events [15]. A large population-based study by Darby
et al. showed that the rate of major coronary events in-
creased by 7.4% for each increase of 1 Gray (Gy) of the
median heart dose (MHD), but the estimated dose to the
LAD did not improve the prediction of coronary events
[4]. The patients were treated before the era of 3D con-
formal RT (3DCRT) and radiation doses to the heart
and to the LAD were estimated from models [4]. An as-
sociation between the MHD and coronary events was re-
cently verified in patients receiving contemporary
3DCRT, with an even stronger association between the
volume of the left ventricle receiving more than 5 Gy
(LV-V5) and subsequent coronary events [16]. Taylor et
al. have shown, using simulated heart doses and more
contemporary RT, an excess of risk rate of 4.1% per Gy
of the MHD [17]. A recent study from the same group
showed a significant correlation between simulated
doses to LAD and later stenosis [18]. The aim of the
present study was to examine whether there is a rela-
tionship between radiation dose to the CAs and a later
coronary stenosis at this location that requires a coron-
ary intervention. All patients received contemporary
3DCRT, which enables patient-specific information on
radiation doses to the CAs. The main focus was on the
high-dose region in the LAD.
Methods
Patients
The study was designed as a case-only study of women ir-
radiated for BC and who subsequently underwent coron-
ary angiography. To identify the study base, women with
BC who had received RT between 1992 and 2012 were se-
lected from the regional breast cancer registries in three
of Sweden’s six health care regions (Uppsala-Örebro,
Stockholm, and the Northern region). The study base was
then linked to the Swedish Coronary Angiography and
Angioplasty Registry (SCAAR), a part of the nationwide
Swedish cardiac register SWEDEHEART [19], to identify
BC patients with a coronary event after RT. Out of these
patients, only women receiving 3DCRT and for whom the
original RT plan was available, were included in the ana-
lysis. Exclusion criteria were bilateral BC and coronary
events registered before RT. Clinicopathological informa-
tion was obtained from the breast cancer registries and
targets, fractionation, and total radiation dose were re-
trieved from the RT charts. Type of coronary investigation
(only angiography or intervention), and in case of inter-
vention, location and type of coronary intervention, body
mass index (BMI), and smoking status was obtained from
SCAAR. The ethical committee of Northern Sweden ap-
proved the study.
Radiotherapy
All information concerning the RT was obtained from
the patients’ individual RT charts. The treatment targets
included the breast tissue alone; the breast tissue and
locoregional lymph nodes (including the axillar,
infra-and supraclavicular lymph nodes); breast tissue,
locoregional lymph nodes, and internal mammary chain
(IMC); the chest wall alone; the chest wall and locore-
gional lymph nodes; the chest wall, locoregional lymph
nodes, and IMC. A number of different fractionation
schedules were used, including hypofractionated sched-
ules, conventionally fractionated schedules, and for a
number of patients, additional boost fields to the tumour
bed. Details regarding radiation targets and fractionation
are shown in Table 1. All included patients were treated
with conventional treatment techniques, using tangential
photon beams or a combination of photon and electron
beams. None of the patients received RT with ABC
techniques.
Delineation of organs at risk
All planning-CTs were performed without intravenous
contrast enhancement. The heart atlas by Feng et al.
[20]. was used as a guideline for the delineation of the
CAs and the heart. The left main coronary artery
(LMCA), the LAD, the proximal left circumflex artery
(LCX), and the right coronary artery (RCA) were delin-
eated. The arteries were divided into segments to local-
ise the stenosis, according to the American Heart
Association guidelines [21], which is consistent with the
registration in SCAAR (Fig. 1). In the majority of the CT
slices, the CAs were visible, but occasionally anatomical
landmarks were followed and the interpolation function
in the treatment planning system (TPS) used. Contour-
ing was performed by hand with either a minimum
brush of 4 mm or with the point-to-point tool, and was
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Year of cancer diagnosis, N (%)
1995–2001 21 (25.9) 31 (30.7) 52 (28.6) 0.76
2002–2008 37 (45.7) 41 (40.6) 78 (42.9)
2009–2012 23 (28.4) 29 (28.7) 52 (28.6)
Age at cancer diagnosis, N (%)
40–49 yrs 4 (4.9) 6 (5.9) 10 (5.5) 0.90
50–59 yrs 19 (23.5) 27 (26.7) 46 (25.3)
60–69 yrs 41 (50.6) 44 (43.6) 85 (46.7)
70–79 yrs 15 (18.5) 22 (21.8) 37 (20.3)
80–83 yrs 2 (2.5) 2 (2.0) 4 (2.2)
Age at diagnosis, median (min-max) 64 (40–84) 64 (44–82) 64 (40–84)
Type of surgery, N (%)
Breast conserving surgery 67 (83.8) 88 (87.0) 155 (85.2) 0.79
Mastectomy 13 (16.2) 11 (12.0) 24 (13.1)
No surgery 0 (0.0) 1 (1.0) 1 (0.5)
Missing data 1 (1.2) 1 (1.0) 2 (1.1)
Endocrine therapy, N (%)
Endocrine therapy 44 (54.3) 52 (51.5) 96 (52.7) 0.77
No endocrine therapy 37 (45.7) 49 (48.5) 86 (47.3)
Chemotherapy, N (%)
Chemotherapy 23 (28.4) 18 (17.8) 41 (22.5) 0.11
No chemotherapy 58 (71.6) 83 (82.2) 141 (77.5)
CT-scan slice thickness, N (%)
< 5 mm 19 (23.5) 20 (19.8) 39 (21.4) 0.92
5 mm 21 (25.9) 28 (27.7) 49 (26.9)
6–9 mm 14 (17.3) 20 (19.8) 34 (18.7)
10 mm 25 (30.9) 33 (32.7) 60 (32.9)
15–16mm 2 (2.5) 0 (0) 2 (1.1)
Treatment planning system, N (%)
TMS 47 (58.0) 59 (58.4) 106 (58.2) 1.0
Oncentra 8 (9.9) 9 (8.9) 17 (9.3)
Eclipse 26 (32.1) 33 (32.7) 59 (32.4)
Algorithm, N (%)
AAA 47 (58.0) 60 (59.4) 107 (58.8) 0.20
CC 21 (25.9) 33 (32.7) 54 (29.7)
PB 13 (16.0) 8 (7.9) 21 (11.5)
Target, N (%)
Breast 60 (74.1) 80 (79.2) 140 (76.9) 0.82
Breast + regional LN 8 (9.9) 9 (8.9) 17 (9.3)
Breast + regional LN + IMC 0 (0.0) 1 (1.0) 1 (0.5)
Chest wall 1 (1.2) 1 (1.0) 2 (1.1)
Chest wall + regional LN 10 (12.3) 7 (6.9) 17 (9.3)
Chest wall + regional LN + IMC 2 (2.5) 3 (3.0) 5 (2.7)
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adjusted to encompass the arteries with a diameter of
about 4 to 6mm. No extra margin was added. The pa-
tients were contoured by one of the authors and the pro-
cedure was performed blinded regarding the location of
the stenosis. The slice thickness of the CT scans varied
from 2 to 16mm and the majority of the patients (78.6%)
had CT scans with slice thickness between 5 and 10mm.
Reconstruction of delivered dose to cardiac structures
The original planning-CT and delivered treatment plan
were retrieved for each patient in the local TPS of the
department. The TPS used were TMS® (Helax AB,
Sweden), Oncentra® (Elekta, Sweden), and Eclipse®
(Varian Medical Systems Inc., USA). The CA segments
and the whole heart were delineated in each patient’s
original planning-CT and radiation doses to these struc-
tures for each individual patient were recalculated using
the original dose distributions. The treatment plans were
recalculated whenever possible, with the original acceler-
ator and beam model. If the beam data was not available,
the plans were recalculated with newer accelerators and
beam models similar to the original, in order to receive









2.66 Gy × 16 16 (19.8) 3 (3.0) 19 (10.4) 0.001
2.67 Gy × 15 2 (2.5) 1 (1.0) 3 (1.6)
2 Gy x (22–24) 3 (3.7) 2 (2.0) 5 (2.7)
2 Gy x (22–24) + boost 2 Gy × 9 0 (0.0) 1 (1.0) 1 (0.5)
2 Gy x (26–28) 10 (12.3) 8 (7.9) 18 (9.9)
2 Gy × 25 47 (58.0) 83 (82.2) 130 (71.4)
2 Gy × 25 + boost 2 Gy × 5 2 (2.5) 1 (1.0) 3 (1.6)
2 Gy × 25 + boost 2 Gy × 8 1 (1.2) 2 (2.0) 3 (1.6)
Time from RT to SCAAR registration, N (%)
< 2 yrs 22 (27.2) 29 (28.7) 51 (28.0) 0.85
2–4 yrs 15 (18.5) 22 (21.8) 37 (20.3)
4–8 yrs 21 (25.9) 27 (26.7) 48 (26.4)
8+ yrs 23 (28.4) 23 (22.8) 46 (25.3)
Time in years from RT to SCAAR registration, median (min-max) 4.9 (0.1–15.6) 3.9 (0.1–14.0) 5.0 (0.1–15.6)
Patients characteristics by laterality of the tumor. BC Breast cancer, yrs Years, min Minimum, max Maximum, CT Computed tomography, AAA Analytical anisotropic
algorithm, CC Collapsed cone, PB Pencil beam, regional LN Regional lymph nodes i.e.; axillary and supraclavicular lymph nodes, IMC Internal mammary chain, Gy
Gray, RT Radiotherapy, and SCAAR Swedish coronary angiography and angioplasty registry
Fig. 1 The coronay arteries. The coronary arteries; the right coronary artery (RCA), the left main coronary artery (LMCA), the left anterior
descending artery (LAD), and the left circumflex artery (LCX)
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a high agreement between the recalculated dose distri-
butions to the CAs and the original dose given. For pa-
tients receiving boost fields, the boost dose was included
in the dose calculations. Depending on the local practice
of the departments, three different algorithms were used:
The Pencil Beam (PB) (TMS® and Oncentra®), the Col-
lapsed Cone (CC) (Oncentra®), or the Analytical Aniso-
tropic Algorithm (AAA) (Eclipse®). In order to estimate
the difference in dose estimation to the CAs between
the PB and the CC algorithms, the RT plans of two pa-
tients in the present study with right-sided and left-sided
RT respectively, were recalculated with both algorithms.
From the recalculated treatment plans, dose-volume his-
tograms (DVH) were generated for the whole heart and
the delineated CAs. Mean, median, and maximum radi-
ation doses were determined for the heart and for the
CAs in each patient’s individual treatment plan. The
maximum dose was defined as the dose to the single cal-
culation point receiving the highest dose.
Statistical methods
The distributions of radiation dose exposures in all
women were summarised in proportions and in descrip-
tive statistics using minimum, first quartile (Q1), me-
dian, third quartile (Q3), and maximum. In coronary
segment specific analyses, the relation between radiation
dose and coronary intervention (yes/no) was compared
using logistic regression. To account for the elapsed time
since the RT, this time was defined segment-wise. In
case of an intervention, the elapsed treatment time was
calculated from RT start to date of intervention as re-
corded in SCAAR. If no intervention was recorded, the
elapsed treatment time was calculated from start of RT
to last day of follow-up (23rd August 2016) or date of
death, whichever came first. In this case-only study, the
elapsed treatment time cannot be used directly in the lo-
gistic regression as it relates to the outcome in a censor-
ing like manner. Therefore, an actuarial approach to the
issue was applied and the elapsed treatment time was
split in four-week periods. The data was then transferred
to long format based on the actuarial four-week periods,
and logistic regression analyses were performed.
Odds ratios (OR) of coronary intervention by each
coronary segment were estimated. The ORs correspond
to the relative risk of receiving segment-specific inter-
ventions comparing different doses. Models using dose
as a continuous variable (trend test) but also models
where the dose was discretised into categories were per-
formed. For the proximal, mid, and distal RCA, the
LMCA, the proximal LAD, and the LCX, cut-offs for the
lowest category were chosen as the integer value closes
to the median, which represented 1 Gy. In the mid and
distal LAD, the cut-offs were chosen according to the
40th and 80th percentile, which represented 1 and 20
Gy, respectively, and for the mid LAD the 70th percent-
ile, representing 5 Gy, was also used as cut-off. Doses in
the lowest range were defined as references. The model
was adjusted for age (continuous) and year of BC diag-
nosis (continuous), year of registration in SCAAR (con-
tinuous), endocrine therapy (yes/no), chemotherapy
(yes/no), BMI (five categories), and smoking status
(three categories). The same adjustments were included
in models used to assess the risk in relation to time and
the combination of time and dose.




A total of 872 women with a BC diagnosis and a match
in SCAAR were identified (Additional file 1: Figure S1).
Out of these, 602 patients received adjuvant RT, and
their original treatment plans were retrieved. A total of
312 patients were excluded due to lack of a full 3D rep-
resentation of the RT plan or due to technical issues
with reading back RT plans from archives. Furthermore,
85 patients were excluded due to missing RT plans
(registration errors or RT received in other health care
regions). Finally, eight patients were excluded due to bi-
lateral BC, and 15 patients due to a SCAAR entry before
RT. This left a total of 182 patients in the final study
base, with 101 patients treated for left-sided BC and 81
for right-sided BC.
Patient characteristics are shown in Table 1. One hun-
dred and fifty-five (85.2%) patients had breast conserving
surgery (BCS) performed and 140 (76.9%) of these re-
ceived RT to the breast without lymph node irradiation.
Ninety-six (52.7%) and 41 (22.5%) of the patients re-
ceived endocrine therapy and chemotherapy, respect-
ively. The RT was planned in the TMS system for the
majority of the patients. Doses were recalculated for 107
patients (58.5%) using the AAA, 54 (29.7%) with the CC,
and 21 (11.5%) with the PB. Only subtle differences were
observed between the PB and the CC algorithms, when
the RT plans were recalculated with both algorithms, for
one patient with right-sided and left-sided RT, respect-
ively (Additional file 1: Table S1).
Information from the SCAAR, tumour characteristics,
mode of cancer detection, and health care region is pre-
sented in Additional file 1: Table S2. Percutaneous cor-
onary intervention (PCI) was performed in 172 of the
patients and coronary artery by-pass grafting (CABG) in
four of the patients. Ten patients underwent coronary
angiography without any coronary intervention. Myocar-
dial infarction was the most common indication for
intervention and stenosis in one artery branch the most
common finding on the coronary angiography. The
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number and type of coronary interventions are shown in
Table 2, presented by each coronary segment separately.
Radiation doses
In right-sided BC RT, the highest radiation doses were
seen in mid RCA with a median mean dose of 1.6 Gy
and a median maximum dose of 2.2 Gy. The median
mean heart dose was 0.6 Gy. In left-sided BC RT, the
highest doses were found in the mid and distal LAD,
with median mean doses of 3.6 Gy and 26.7 Gy, and me-
dian maximum doses of 7.9 Gy and 44.8 Gy, respectively
(Fig. 2 and Additional file 1: Table S3). The median
mean doses to the whole LAD and the heart was 10.6
Gy and 2.7 Gy, respectively.
Relationship between radiation dose and coronary
intervention
The ORs of coronary intervention by each coronary seg-
ment, for mean and maximum doses were estimated
(Fig. 3 and Additional file 1: Table S4). In the mid LAD,
a total of 52 coronary events were registered. The odds
of coronary events in mid LAD increased with dose
(p-value for trend test = 0.005).
Women receiving mean doses of 1–5 Gy in the mid
LAD had an adjusted OR of 0.90 (95% CI 0.47–1.74),
compared to women receiving 0–1 Gy. Women receiving
mean doses of 5–20 Gy in the mid LAD had an adjusted
OR of 1.24 (95% CI 0.52–2.95) for a later coronary inter-
vention, compared to women receiving 0–1 Gy. Women
receiving mean doses over 20 Gy in mid LAD had an ad-
justed OR of 5.23 (95% CI 2.01–13.6) for a later coron-
ary intervention in comparison with women receiving
0–1 Gy. In distal LAD, there were few interventions and
no statistically significant OR for a coronary intervention
was found. In the proximal LCX, an adjusted OR of 0.22
(95% CI 0.07–0.64) for a later coronary intervention was
seen in women receiving mean doses between 1 and 4
Gy, compared to women receiving 0–1 Gy.
The ORs of coronary intervention over time from
the RT exposure were estimated (Table 3). The
elapsed treatment time of 0–4 years, 4–8 years, and
over 8 years was studied, with elapsed treatment time
of 4–8 years defined as reference. There seemed to be
an accumulation of interventions in the first 4 years
after RT and at elapsed treatment times of 8 years or
longer. When time was combined with dose, an OR
of 8.21 (95% CI 2.07–32.5) for mean dose over 15 Gy
and of 5.39 (95% CI 1.72–16.9) for maximum dose
over 40 Gy was observed for coronary events in mid
LAD and elapsed treatment time of 8 years or longer.
Mean doses of 0–5 Gy, maximum doses of 0–10 Gy,
and elapsed treatment time of 0–4 years were defined
as reference (Additional file 1: Table S5).
Discussion
Our main finding was a positive association between
mean radiation doses to mid LAD and a later coronary
stenosis that required intervention at that specific loca-
tion, with a statistically significant five-fold increase of
OR when comparing mid LAD mean doses over 20 Gy
to doses of 0–1 Gy. Since IHD is a long-term side effect
of RT, the combination of dose and time was also stud-
ied, which gave an even higher OR than dose alone. In
the high-dose region of distal LAD, there were few inter-
ventions performed due to the narrow lumen of the ves-
sel, rendering it technically unfeasible. Thus, the
prerequisites to study risk of stenosis in this segment
were not at hand.
Dose reconstructions were performed in the patients’
original planning-CTs and the information from SCAAR
contributed with patient-specific location of the stenosis
and thus confirmed its clinical significance. This study is
to the authors’ knowledge the largest retrospective study
where dose reconstruction to the CAs has been per-
formed in the patient’s original planning CT. This en-
ables a reliable estimation of radiation doses to the
specific site where the stenosis was subsequently local-
ised, thus taking the patient-specific thoracic anatomy
and dose distribution into account. Due to individual
variation in anatomy, radiation dose distribution can dif-
fer significantly [23].
In the proximal LCX, a statistically significant de-
creased OR of 0.22 for a later coronary intervention was
seen in women receiving mean doses of 1–4 Gy com-
pared to women receiving 0–1 Gy, thus suggesting lower
risk of coronary intervention at higher doses. Since sev-
eral studies have shown an increase in coronary stenosis
at higher radiation doses [4, 16], there seem to be no
Table 2 Coronary intervention presented by each coronary segment separately
Proximal RCA Mid RCA Distal RCA LMCA Proximal LAD Mid LAD Distal LAD Proximal LCX
Stent 35 41 14 4 41 50 6 22
Intervention without stent 0 1 1 0 2 0 1 3
Coronary artery by-pass grafting 1 2 1 1 1 2 0 3
Coronary segment not intervened 146 138 166 177 138 130 175 154
Coronary intervention presented by each coronary segment separately. RCA Right coronary artery, LMCA Left main coronary artery, LAD Left anterior descending
artery, and LCX Left circumflex artery
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biological rationale supporting higher doses being pro-
tective. The threshold radiation dose for injury to the
coronary arteries is unknown and it may be that 1–4 Gy
in LCX is a radiation dose too low, to affect our end-
point of coronary injury, PCI. The relevance of this find-
ing is unclear, and due to the small number of events at
this location and the low radiation doses, it may be a
chance finding.
The estimation of radiation doses in the present study
still suffers from uncertainties. The CAs move due to
cardiac and breathing movements, while the dose esti-
mation is done in a static image. Steep dose gradients in
the anatomical region may lead to uncertainty in dose
estimations in small structures like the CAs. The slice
thickness of the planning-CTs varied due to technical
improvements over time, with thicker slices in the be-
ginning of the study period, implicating fewer dose cal-
culation points. The majority of the patients had
planning-CTs with a slice thickness of 5 to 10 mm. Since
the contouring was adjusted to encompass the CAs with
a diameter of 4 to 6 mm, the CT slice thickness of pa-
tients planning-CTs is a limitation with the study. This
may contribute to uncertainties in dose estimations.
Furthermore, all planning-CTs in the present study were
performed without intravenous contrast media accord-
ing to the standard of care in the clinics, and it is likely
that using contrast enhancement would have improved
the consistency of the contouring of the CAs.
However, a subgroup of 32 women were initially stud-
ied to assess the degree of inter-observer variation in de-
lineating the CAs in the patient’s planning-CT and the
results have been published elsewhere [12]. To summar-
ise, the RCA, the LMCA, and the LAD were delineated
by three radiation oncologists in a blinded procedure,
and the contouring was made by hand in the same man-
ner as in the present study. The distances between the
centres of the delineated arteries were measured, and to
assess the variance in estimated doses, the intraclass cor-
relation coefficient (ICC) was derived as a measure of
agreement between the delineating oncologists. A me-
dian mean distance of 2 to 8 mm in the RCA, and of 1
to 4mm in the LMCA-LAD, was seen between the cen-
tres of the different delineations. An ICC of 0.77 to 0.91
was seen for RCA and of 0.84 to 0.99 for the
LMCA-LAD, which was considered as an acceptable
consistency [12].
Fig. 2 Distribution of coronary radiation doses. Percent of women (Y-axis), receiving at least the radiation dose to the heart and to eight coronary
segments as displayed on the X-axis. Results presented by breast cancer laterality, and maximum and mean doses. Breast cancer (BC), Gray (Gy),
right coronary artery (RCA), left main coronary artery (LMCA), left anterior descending artery (LAD), and left circumflex artery (LCX)
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Another limitation is the use of the PB dose calcula-
tion algorithm in 11.5% of the patients, which may influ-
ence the dose estimates close to low-density tissues, as
the lung. Thorsen et al. have shown when recalculating
from PB to AAA dose algorithms, that there are no sig-
nificant differences between the estimated doses to the
LMCA and LAD in left-sided BC, but a significant 0.36–
0.42 Gy decrease of the estimated MHD [24]. Moreover,
only small differences were observed in a subset of pa-
tients in this study when dose estimation to the CAs be-
tween the PB and the CC algorithms were compared
and thus the use of different algorithms was considered
less likely to affect the results.
The dose-response assessments of CA stenosis were
based on the comparison of risk of stenosis in segments
receiving low doses with segments receiving high doses.
Absolute risk cannot be estimated due to lack of a con-
trol group of patients receiving RT without developing
CA stenosis. Neither was it possible to quantify an esti-
mated increase in coronary events per Gy, due to the
relatively low number of events. The distal LAD received
the highest estimated doses but had few interventions.
PCI is rarely technically feasible in the narrow lumen of
distal LAD, which is an explanation to the low interven-
tion and event rate. Since the choice of end-point in the
study was coronary event requiring intervention, based
on information from SCAAR, it was not possible to
consider any radiation-induced damage to parts of the
heart supplied by the distal LAD.
The patients in the present study were treated before
techniques of ABC were implemented in Sweden. Since
the MHD and doses to the LAD are shown to be consid-
erably lower with these techniques compared to conven-
tional RT techniques, the risk of IHD would likely be
lower when ABC techniques are used [13, 14].
Whether the dose to the LAD or the MHD is the
best predictor of later coronary events has been stud-
ied in recent studies [4, 16, 25]. Darby et al. showed
an increase in coronary events of 7.4% per Gy in
MHD, but prediction was not improved by including
LAD in the model [4]. However, in a more recent
study from the same group, doses to LAD were
shown to be relevant [18]. In a study using modern
3DCRT and delineating the cardiac structures, the
dose to the left ventricle (LV-V5) seemed to be a bet-
ter predictor for acute cardiac events than the mean
heart dose [16]. These studies recorded coronary
events of any site, not only in LAD. In contrast, a
study by Moignier et al. [25] of Hodgkin’s lymphoma
patients estimated doses to specific coronary segments
and later stenosis at these sites. In agreement with
the present study, a significant dose-response relation-
ship between dose and a later coronary stenosis in
this segment was shown, with an estimated increase
Fig. 3 Odds ratio of coronary intervention. Odds ratio (OR) of coronary intervention by coronary artery segment for mean doses. Right coronary
artery (RCA), left main coronary artery (LMCA), left anterior descending artery (LAD), left circumflex artery (LCX), confidence interval (CI), Gray (Gy),
reference (Ref.), and non applicable (NA). *Adjusted for age at breast cancer (BC) diagnosis, year of BC diagnosis, year of registration in
the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), endocrine therapy, chemotherapy, BMI, and smoking status
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in coronary events of 4.9% per Gy [25]. In a previous
study in BC patients by our group, by estimating ra-
diation doses in specific coronary parts, a significant
association between doses to individual coronary seg-
ments and later stenosis at high-dose regions was
found [10]. Thus, even if MHD is a significant risk
factor for the overall risk of later coronary event,
these three studies demonstrate a significant associ-
ation between radiation doses to specific coronary ar-
tery segments and later stenosis at the same site.
Table 3 Odds ratio of coronary event over time
Number of women Number of events Crude analysis Adjusted modela
OR 95% CI OR 95% CI
Proximal RCA
0–4 years 27 7 2.31 (0.98–5.44) 2.22 (0.94–5.23)
4–8 years 49 21 1.00 Ref. 1.00 Ref.
8+ years 106 8 1.12 (0.41–3.10) 1.18 (0.42–3.29)
Mid RCA
0–4 years 30 25 1.89 (0.91–3.94) 1.74 (0.83–3.64)
4–8 years 50 10 1.00 Ref. 1.00 Ref.
8+ years 102 9 0.91 (0.37–2.23) 1.00 (0.4–2.48)
Distal RCA
0–4 years 15 9 2.42 (0.66–8.95) 2.03 (0.54–7.59)
4–8 years 50 3 1.00 Ref. 1.00 Ref.
8+ years 117 4 1.31 (0.29–5.84) 1.71 (0.38–7.82)
LMCA
0–4 years 8 1 0.82 (0.05–13.1) NA
4–8 years 54 1 1.00 Ref.
8+ years 120 3 2.94 (0.31–28.3)
Proximal LAD
0–4 years 24 20 1.20 (0.60–2.42) 1.18 (0.58–2.38)
4–8 years 55 13 1.00 Ref. 1.00 Ref.
8+ years 103 11 0.89 (0.40–1.98) 0.93 (0.41–2.10)
Mid LAD
0–4 years 30 24 1.30 (0.67–2.51) 1.23 (0.63–2.38)
4–8 years 54 14 1.00 Ref. 1.00 Ref.
8+ years 98 14 1.07 (0.51–2.25) 1.16 (0.55–2.46)
Distal LAD
0–4 years 9 2 1.65 (0.15–18.2) NA
4–8 years 52 1 1.00 Ref.
8+ years 121 4 3.93 (0.44–35.2)
Proximal LCX
0–4 years 18 12 2.40 (0.77–7.45) 2.18 (0.70–6.78)
4–8 years 49 4 1.00 Ref. 1.00 Ref.
8+ years 115 12 3.08 (0.99–9.54) 4.12 (1.31–13.0)
Any segment
0–4 years 79 78 1.21 (0.82–1.79) 1.10 (0.74–1.63)
4–8 years 45 38 1.00 Ref. 1.00 Ref.
8+ years 58 45 2.22 (1.44–3.43) 2.58 (1.65–4.01)
Odds ratio of coronary event over time. RCA Right coronary artery, LMCA Left main coronary artery, LAD Left anterior descending artery, LCX Left circumflex artery,
OR Odds ratio, CI Confidence interval, Ref. Reference, and NA Non applicable
aAdjusted for age at breast cancer (BC) diagnosis, year of BC diagnosis, year of registration in the Swedish Coronary Angiography and Angioplasty Registry
(SCAAR), endocrine therapy, chemotherapy, BMI, and smoking status
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Conclusions
In women receiving 3DCRT for BC between 1992 and
2012, radiation doses to the LAD remained high and
were associated with an increased requirement of coron-
ary intervention in mid LAD. The results support that
radiation dose to the LAD should be considered in RT
treatment planning and kept as low as possible, while as-
suring full target coverage. Further development and op-
timisation of treatment techniques in order to reduce
the dose to LAD, and implementation of heart-sparing
RT techniques in the clinical practice is of importance,
since minimising the dose to LAD is expected to dimin-
ish the risk of later radiation-induced stenosis.
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